慢性阻塞性肺病 (COPD) 中的呼吸道微生物组:临床医生的指南
Wei Ling Yolanda Koo1, Kai Xian Thng1,2, Pei Yee Tiew1,3,4
1Lee Kong Chian School of Medicine, Nanyang Technological University, 308232 Singapore, Singapore.
肺部微生物组在慢性阻塞性肺病 (COPD) 中发生变化,影响疾病的进展和结果. 了解这些微生物转变为COPD管理中的新诊断和治疗策略提供了潜力.
科学领域:
- 肺部医学 肺部医学
- 微生物学 微生物学
- 基因组学就是基因组学.
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种具有重大健康影响的渐进性呼吸道疾病.
- 人们越来越认识到肺微生物组在COPD病变发生中的作用,这涉及复杂的微生物-代谢-免疫-炎症相互作用.
- 呼吸道细菌,病毒和真菌群体中的失生症与COPD进展和恶化有关.
研究的目的:
- 审查目前关于COPD肺部微生物组的研究.
- 探索COPD微生物组变化的临床相关性.
- 讨论微生物组数据作为COPD的诊断和预后工具的潜力.
主要方法:
- 关于将微生物组数据与COPD中的其他omics整合的研究的文献综述.
- 对COPD和相关重叠综合征中的微生物转移研究的分析.
- 关于肺微生物组失生症的临床影响的研究结果的综合.
主要成果:
- 肺部微生物组在COPD患者中发生显著变化,影响疾病的进展和恶化.
- 微生物组失生症与COPD的发病有关,并影响临床结果.
- 微生物组分析揭示了COPD新型诊断和预后生物标志物的潜力.
结论:
- 微生物组研究为COPD病原和进展提供了关键的见解.
- 了解肺微生物组的变化是开发COPD个性化,精准医学方法的关键.
- 将微生物组数据纳入临床实践对于优化COPD管理和患者治疗结果至关重要.
更多相关视频
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
相关概念视频
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
